← All trials
NCT04277637
Phase 1Interventional
Includes initial studies to determine the metabolism and pharmacologic actions of drugs in humans, the side effects associated with increasing doses, and to gain early evidence of effectiveness; may include healthy participants and/or patients.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Feb 28, 2020
- Primary completion
- Mar 25, 2023
- Completion date
- Jun 26, 2026
- First posted
- Feb 20, 2020
- Last posted
- Feb 20, 2020
- Enrollment
- 160
- Arms / groups
- 3 / —
- Source
- AACT · ingestion pipeline
Sponsors
- BeOne MedicinesLead sponsor
- BeOne MedicinesStudy director
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.